Hepatosplenic T-cell Lymphoma: Recent Progress and Future Considerations
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes. -
Expert Q&A: Understanding the Oncogenic Role of HIV in Burkitt Lymphoma
While the rate of certain HIV-linked non-Hodgkin lymphomas has declined since the introduction of ART, the incidence of Burkitt lymphoma has remained steady. -
G-CSF Appears Safe in CAR-T–Treated Patients With Refractory/Relapsed B-Cell Lymphoma
The treatment reduced hospital stay but not neutropenia duration or infection rate. -
Examining Progress and Future Directions in Follicular Lymphoma Treatment
Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
VIDEO SERIES
LYMPHOMA NEWS
Recall of Specific Types of Breast Implants and Tissue Expanders Has Far-Reaching Impact on Patients With Breast Cancer
Radiotherapy Response Time Did Not Dictate Outcomes for Gastrointestinal Low-Grade B-Cell Lymphoma
COVID-19, SARS-CoV-2 Infection Phenotypes Vary With Different Tumor Subtypes
Waldenström Macroglobulinemia Treated With Ixazomib Combination Therapy: Long-Term Follow-Up
Low-Dose Anti-PD1 Therapies in Relapsed/Refractory Classical Hodgkin Lymphoma
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
